1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,450 | 6,800 | 08:16 |
► 06.08.: | | | | | | | | |
► 05.08.: | | | | | | | | | 17:30
► Aktueller 4BASEBIO Börsenkurs + Xetra-Orderbuch
► 05.08.: | | | | | | | | | 17:30
► Aktueller 4BASEBIO Börsenkurs + Xetra-Orderbuch
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 22,200 | 30 | |||
| 15,000 | 15 | |||
| 11,000 | 500 | |||
| 6,800 | 1.564 | |||
| 6,350 | 500 | |||
| 6,250 | 721 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 721 | 5,950 | |||
| 1.564 | 5,450 | |||
| 700 | 4,740 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 4.046 | 0,833 | 3.369 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.07. | 4basebio Plc - Grant of Options & Director/PDMR Dealing | 348 | PR Newswire | 4basebio Plc - Grant of Options & Director/PDMR Dealing
PR Newswire
LONDON, United Kingdom, July 22
4basebio PLC
("4basebio"... ► Artikel lesen | |
| 08.07. | 4basebio Plc - Director Appointment | 565 | PR Newswire | 4basebio Plc - Director Appointment
PR Newswire
LONDON, United Kingdom, July 08
4basebio PLC
("4basebio" or the "Company")
... ► Artikel lesen | |
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 30.06. | 4basebio Plc - Result of AGM & Issue of Options | 398 | PR Newswire | 4basebio Plc - Result of AGM & Issue of Options
PR Newswire
LONDON, United Kingdom, June 30
4basebio PLC
("4basebio"... ► Artikel lesen | |
| 16.06. | 4basebio Plc - Notice of Investor Presentation | 393 | PR Newswire | 4basebio Plc - Notice of Investor Presentation
PR Newswire
LONDON, United Kingdom, June 16
4basebio... ► Artikel lesen | |
| 15.06. | IN BRIEF: 4basebio appoints Jeff Coller to Strategic Advisory Board | 1 | Alliance News |
1 2 3 4 5 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 08:10 | Bavarian Nordic A/S: Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years | GlobeNewswire (Europe) | MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virusApproval further strengthens MVA-BN's position in... ► Artikel lesen | |
| Do | Attovia Therapeutics, Inc.: Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | GlobeNewswire (Europe) | SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia") (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for... ► Artikel lesen | |
| Do | Oculis Holding AG: Oculis Reports Q2 2026 Financial Results and Provides Company Update | GlobeNewswire (Europe) | ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with... ► Artikel lesen | |
| Do | Surrozen, Inc.: Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update | GlobeNewswire (Europe) | Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipated... ► Artikel lesen | |
| Do | Cellectis Reports Financial Results for the Second Quarter 2026 | GlobeNewswire (Europe) | Lasme-cel: Pivotal Phase 2 in r/r B-ALL (BALLI-01) FDA RMAT designation received for lasme-cel Full Phase 1 clinical data from the BALLI-01 trial presented at EHA 2026 Pivotal Phase 2 first interim... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu 4BASEBIO PLC finden Sie auf Wallstreet Online.